Expertise in
15
conditions

Dr. Lindsay A. Rein

Hematology
2400 Pratt St, 
Durham, NC 
Offers Telehealth
18 Years of Experience
Referral required
Expertise in
15
conditions
2400 Pratt St, 
Durham, NC 

Overview

I have the privilege of caring for patients with various myeloproliferative neoplasms including, polycythemia vera, essential thrombocytosis, primary myelofibrosis, systemic mastocytosis, and chronic myeloid leukemia. My goal is to provide the best possible care for each individual patient in an era where the number of therapeutic options for patients with myeloproliferative neoplasms is rapidly expanding. As a clinical investigator leading several clinical studies in both early and late stages of development, I strive to offer patients access to investigational agents with novel mechanisms of action via participation in clinical trials. I believe that every patient has a unique diagnosis and personal experience with their cancer. I aim to consider the disease, the patient and individual care goals in partnering with patients to develop and implement personalized treatment plans.

Dr. Rein is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Systemic Mastocytosis, Myeloproliferative Neoplasms (MPN), Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Rein is board certified in American Board Of Internal Med, Medical Oncology and American Board Of Internal Med, Hematology. She is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 2 clinical trials.

Graduate Institution

University Of North Dakota School Of Medicine And Health Sciences|, 2008

Specialties

Hematology

Licenses

Internal Medicine in NC

Board Certifications

American Board Of Internal Med, Medical Oncology
American Board Of Internal Med, Hematology

Fellowships

Hematology and Medical Oncology, Duke University Medical Center

Hospital Affiliations

Duke University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Duke Blood Cancer Center
2400 Pratt St, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
View 1 Less Clinical Trial

26 Total Publications

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Journal: Lancet regional health. Americas
Published: March 25, 2026
Similar Doctors
Expertise in
39
conditions
Dr. Tapan Kadia
Hematology
Expertise in
39
conditions
Dr. Tapan Kadia
Hematology
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (21.2 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist practicing medicine in Cary, North Carolina. Dr. Kadia is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Prolymphocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
33
conditions
Dr. Prithviraj Bose
Hematology
Expertise in
33
conditions
Dr. Prithviraj Bose
Hematology
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (21.2 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist practicing medicine in Cary, North Carolina. Dr. Bose is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
32
conditions
Dr. Nigel Key
Hematology | Oncology
Expertise in
32
conditions
Dr. Nigel Key
Hematology | Oncology
Referral may be required

UNC Hospitals Outpatient Center At Eastowne

100 Eastowne Dr, 
Chapel Hill, NC 
 (5.7 miles away)
984-974-2695
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nigel Key is a Hematologist and an Oncologist practicing medicine in Chapel Hill, North Carolina. Dr. Key is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Hemophilia B, Hemophilia A, Blood Clots, and Sickle Cell Disease.

Frequently Asked Questions about Dr. Lindsay A. Rein

How do I make an appointment with Dr. Lindsay A. Rein?

You can book an appointment with Dr. Lindsay A. Rein by calling their office at 919-684-8964. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lindsay A. Rein a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lindsay A. Rein is classified as an Distinguished expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lindsay A. Rein specialize in?

While Dr. Lindsay A. Rein is a Hematology, they have specific expertise in Myelofibrosis, Systemic Mastocytosis, and Myeloproliferative Neoplasms (MPN). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Lindsay A. Rein participate in research or clinical trials?

Yes. Dr. Lindsay A. Rein has published 26 articles and abstracts on conditions like Myelofibrosis. You can view a list of Dr. Lindsay A. Rein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lindsay A. Rein accept my insurance?

Dr. Lindsay A. Rein accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 919-684-8964 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rein's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile